SKI-II - CAS# 312636-16-1 size:10mg solid Smiles: CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C

Smiles: CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C

3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S

1262036-50-9

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Bielecki P

SKI-II - CAS# 312636-16-1 size:10mg solid Smiles: CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)CSKI II, CAS No. 312636 16 1, is a selective non lipid inhibitor of sphingosine kinase (IC50 = 0. 5 M). nhibits acute myelogenous leukemia cell growth in vitro and in vivo. SKI II was more efficient than two known SphK1 inhibitors SK1 I and FTY720 in inhibiting AML cells. Meanwhile, it induced dramatic apoptosis in above AML cells, and the cytotoxicity by SKI II was almost reversed by the general caspase inhibitor z VAD fmk. SKI II treatment inhibited